Targeting DLK1 in neuroblastoma
- PMID: 39486413
- DOI: 10.1016/j.ccell.2024.10.006
Targeting DLK1 in neuroblastoma
Abstract
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue of Cancer Cell, Hamilton et al. combine proteomics, transcriptomics, epigenomics, and dependency databases to identify DLK1, a novel immunotherapeutic target for neuroblastoma.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The author declares no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
